热门资讯> 正文
Janux Therapeutics GAAP每股收益为-0.30美元，击败0.03美元
2024-05-08 05:59
- Janux Therapeutics press release (NASDAQ:JANX): Q1 GAAP EPS of -$0.30 beats by $0.03.
- As of March 31, 2024, Janux reported cash and cash equivalents and short-term investments of $651.8 million compared to $344.0 million at December 31, 2023.
- Shares -1.63% AH.
More on Janux Therapeutics
- Janux Therapeutics: A Prime Target In Cancer Care's M&A Game
- Janux Therapeutics: Yes There's New Data; No It's Not A Buy Here
- Trial Data Triggers Massive Rally In Janux Therapeutics
- Janux Therapeutics gains amid renewed takeover speculation
- Janux Therapeutics jumps as much as 28% on heels of Deciphera buyout deal
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
